Anika Therapeutics (ANIK) Tax Provisions (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Tax Provisions data on file, last reported at $235000.0 in Q1 2026.

• On a quarterly basis, Tax Provisions rose 135.0% year-over-year to $235000.0 in Q1 2026; TTM through Mar 2026 was $746000.0, a 87.81% decrease from a year earlier, with the FY2025 full-year figure at $611000.0, down 89.92% from the prior year.
• Tax Provisions for Q1 2026 stood at $235000.0, up from -$1.1 million in the prior quarter.
• Over the last five years, Tax Provisions for ANIK reached as high as $9.1 million in Q4 2023 and fell as low as -$1.7 million in Q1 2023.
• Historically, Tax Provisions has averaged $918647.1 across 5 years, with a median of $100000.0 in 2025.
• Across the five-year window, Tax Provisions plunged 269.57% in 2022 and soared 542.0% in 2024, its largest moves.
• Year by year, Tax Provisions stood at $4.5 million in 2022, then jumped by 100.07% to $9.1 million in 2023, then plunged by 72.1% to $2.5 million in 2024, then sank by 143.13% to -$1.1 million in 2025, then surged by 121.58% to $235000.0 in 2026.
• Per Business Quant data, the three most recent Tax Provisions figures were $235000.0 in Q1 2026, -$1.1 million in Q4 2025, and $900000.0 in Q3 2025.